BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Rev Clin Pharmacol. 2019;12:909-915. [PMID: 31424296 DOI: 10.1080/17512433.2019.1654858] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
Number Citing Articles
1 Metwally M, Ragab R, Abdel Hamid HS, Emara N, Elkholy H. Helicobacter pylori Antibiotic Resistance in Egypt: A Single-Center Study. Infect Drug Resist 2022;15:5905-13. [PMID: 36312439 DOI: 10.2147/IDR.S386082] [Reference Citation Analysis]
2 Karbalaei M, Keikha M, Talebi Bezmin Abadi A. Prevalence of Primary Multidrug-resistant Helicobacter pylori in Children: A Systematic Review and Meta-analysis. Arch Med Res 2022:S0188-4409(22)00101-1. [PMID: 36089418 DOI: 10.1016/j.arcmed.2022.08.010] [Reference Citation Analysis]
3 Casado J, Lanas Á, González A. Two-component regulatory systems in Helicobacter pylori and Campylobacter jejuni: Attractive targets for novel antibacterial drugs. Front Cell Infect Microbiol 2022;12:977944. [DOI: 10.3389/fcimb.2022.977944] [Reference Citation Analysis]
4 Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Tratamiento empírico vs tratamiento basado en susceptibilidad para erradicar H.pylori: ¿es posible cambiar este paradigma usando métodos moleculares modernos? Revista de Gastroenterología de México 2022;87:330-341. [DOI: 10.1016/j.rgmx.2022.01.007] [Reference Citation Analysis]
5 Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods? Revista de Gastroenterología de México (English Edition) 2022;87:330-341. [DOI: 10.1016/j.rgmxen.2022.06.003] [Reference Citation Analysis]
6 Abdi S, Ataei S, Abroon M, Majma Sanaye P, Abbasinazari M, Farrokhian A. A Comprehensive Review of the Role of Complementary and Dietary Medicines in Eradicating Helicobacter pylori. Iran J Pharm Res 2022;21. [DOI: 10.5812/ijpr-127030] [Reference Citation Analysis]
7 Zhou Y, Zhong Z, Hu S, Wang J, Deng Y, Li X, Chen X, Li X, Tang Y, Li X, Hao Q, Liu J, Sang T, Bo Y, Bai F. A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China. Antimicrob Agents Chemother 2022;:e0218821. [PMID: 35652644 DOI: 10.1128/aac.02188-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 González A, Casado J, Gündüz MG, Santos B, Velázquez-campoy A, Sarasa-buisan C, Fillat MF, Montes M, Piazuelo E, Lanas Á. 1,4-Dihydropyridine as a Promising Scaffold for Novel Antimicrobials Against Helicobacter pylori. Front Microbiol 2022;13:874709. [DOI: 10.3389/fmicb.2022.874709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Meng F, Tao H, Mi Y, Yang T, Wang X, Go Y, Lin Y, Wang G. Nanocluster-mediated photothermia improves eradication efficiency and antibiotic sensitivity of Helicobacter pylori. Cancer Nano 2022;13. [DOI: 10.1186/s12645-022-00121-2] [Reference Citation Analysis]
10 Krzyżek P, Migdał P, Grande R, Gościniak G. Biofilm Formation of Helicobacter pylori in Both Static and Microfluidic Conditions Is Associated With Resistance to Clarithromycin. Front Cell Infect Microbiol 2022;12:868905. [DOI: 10.3389/fcimb.2022.868905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Boyanova L, Hadzhiyski P, Markovska R, Gergova R. Investigation of multidrug-resistant Helicobacter pylori in pediatric patients: A Bulgarian study and literature data. Acta Microbiol Immunol Hung 2022. [PMID: 35107441 DOI: 10.1556/030.2022.01682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zhang P, He Q, Song D, Wang Y, Liu X, Ding G, Xing W. Association of Helicobacter pylori Infection With Carotid Atherosclerosis in a Northern Chinese Population: A Cross-Sectional Study. Front Cardiovasc Med 2022;8:795795. [DOI: 10.3389/fcvm.2021.795795] [Reference Citation Analysis]
13 Witkowska D, Szebesczyk A, Wątły J, Braczkowski M, Rowińska-Żyrek M. A Comparative Study on Nickel Binding to Hpn-like Polypeptides from Two Helicobacter pylori Strains. Int J Mol Sci 2021;22:13210. [PMID: 34948007 DOI: 10.3390/ijms222413210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Choi YI, Lee SM, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Lee SM, Jeong JY, Park DK. Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study. Antibiotics (Basel) 2021;10:1242. [PMID: 34680822 DOI: 10.3390/antibiotics10101242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mehrotra T, Devi TB, Kumar S, Talukdar D, Karmakar SP, Kothidar A, Verma J, Kumari S, Alexander SM, Retnakumar RJ, Devadas K, Ray A, Mutreja A, Nair GB, Chattopadhyay S, Das B. Antimicrobial resistance and virulence in Helicobacter pylori: Genomic insights. Genomics 2021;113:3951-66. [PMID: 34619341 DOI: 10.1016/j.ygeno.2021.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613-29. [PMID: 34002081 DOI: 10.1038/s41575-021-00449-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 64.0] [Reference Citation Analysis]
17 Resina E, Gisbert JP. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics (Basel) 2021;10:1028. [PMID: 34572610 DOI: 10.3390/antibiotics10091028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Choi YI, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Seo JY, Park DK. Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients. World J Gastroenterol 2021; 27(31): 5247-5258 [PMID: 34497448 DOI: 10.3748/wjg.v27.i31.5247] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Attaran B, Salehi N, Ghadiri B, Esmaeili M, Kalateh S, Tashakoripour M, Eshagh Hosseini M, Mohammadi M. The penicillin binding protein 1A of Helicobacter pylori, its amoxicillin binding site and access routes. Gut Pathog 2021;13:43. [PMID: 34183046 DOI: 10.1186/s13099-021-00438-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gollapalli P, G TS, H M, Shetty P, N SK. Network topology analysis of essential genes interactome of Helicobacter pylori to explore novel therapeutic targets. Microb Pathog 2021;158:105059. [PMID: 34157412 DOI: 10.1016/j.micpath.2021.105059] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
21 Sayer JR, Walldén K, Koss H, Allan H, Daviter T, Gane PJ, Waksman G, Tabor AB. Design, synthesis, and evaluation of peptide-imidazo[1,2-a]pyrazine bioconjugates as potential bivalent inhibitors of the VirB11 ATPase HP0525. J Pept Sci 2021;:e3353. [PMID: 34142414 DOI: 10.1002/psc.3353] [Reference Citation Analysis]
22 Choudhury A, Ortiz P, Kearney CM. In situ treatment of H. pylori infection in mice stomach with bioengineered probiotic bacteria releasing guided Antimicrobial peptides.. [DOI: 10.1101/2021.06.11.448139] [Reference Citation Analysis]
23 Choudhury A, Ortiz P, Kearney CM. In vitro inhibition of H. pylori in a preferential manner using bioengineered L. lactis releasing guided Antimicrobial peptides.. [DOI: 10.1101/2021.06.11.448109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gong M, Han Y, Wang X, Tao H, Meng F, Hou B, Sun BB, Wang G. Effect of Temperature on Metronidazole Resistance in Helicobacter pylori. Front Microbiol 2021;12:681911. [PMID: 34093508 DOI: 10.3389/fmicb.2021.681911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
25 Kobayashi J, Kawakubo M, Fujii C, Arisaka N, Miyashita M, Sato Y, Komura H, Matoba H, Nakayama J. Cholestenone functions as an antibiotic against Helicobacter pylori by inhibiting biosynthesis of the cell wall component CGL. Proc Natl Acad Sci U S A 2021;118:e2016469118. [PMID: 33853940 DOI: 10.1073/pnas.2016469118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 Mi M, Wu F, Zhu J, Liu F, Cui G, Wen X, Hu Y, Deng Z, Wu X, Zhang Z, Qi T, Chen Z. Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China. Infect Drug Resist 2021;14:535-45. [PMID: 33603417 DOI: 10.2147/IDR.S287631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Gontijo MTP, Vidigal PMP, Lopez MES, Brocchi M. Bacteriophages that infect Gram-negative bacteria as source of signal-arrest-release motif lysins. Res Microbiol 2021;172:103794. [PMID: 33347948 DOI: 10.1016/j.resmic.2020.103794] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
29 Krzyżek P, Gościniak G, Fijałkowski K, Migdał P, Dziadas M, Owczarek A, Czajkowska J, Aniołek O, Junka A. Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate or Sertraline, to Fight against Helicobacter pylori Lawn Biofilm. Int J Mol Sci 2020;21:E9507. [PMID: 33327555 DOI: 10.3390/ijms21249507] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
30 Di Fermo P, Di Lodovico S, Amoroso R, De Filippis B, D'Ercole S, Di Campli E, Cellini L, Di Giulio M. Searching for New Tools to Counteract the Helicobacter pylori Resistance: The Positive Action of Resveratrol Derivatives. Antibiotics (Basel) 2020;9:E891. [PMID: 33322025 DOI: 10.3390/antibiotics9120891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
31 Cano A, Ettcheto M, Espina M, López-Machado A, Cajal Y, Rabanal F, Sánchez-López E, Camins A, García ML, Souto EB. State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. J Nanobiotechnology 2020;18:156. [PMID: 33129333 DOI: 10.1186/s12951-020-00714-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
32 Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, Xie WR, He XX. The Efficacy of Washed Microbiota Transplantation on Helicobacter pylori Eradication: A Pilot Study. Gastroenterol Res Pract 2020;2020:8825189. [PMID: 33133183 DOI: 10.1155/2020/8825189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Isaza-gómez E, Ángel-gonzález MS, Ocampo-muñoz M, Díaz-quintero CA, Molina-céspedes IC, Velásquez-martínez MA, Posada-moreno P, Salazar-ochoa S. Controversias en cirugía: Erradicación del Helicobacter pylori ¿Terapia a todos o según indicaciones usuales? Rev Colomb Cir 2020;35:665-674. [DOI: 10.30944/20117582.563] [Reference Citation Analysis]
34 Raj R, Agarwal N, Raghavan S, Chakraborti T, Poluri KM, Kumar D. Exquisite binding interaction of 18β-Glycyrrhetinic acid with histone like DNA binding protein of Helicobacter pylori: A computational and experimental study. International Journal of Biological Macromolecules 2020;161:231-46. [DOI: 10.1016/j.ijbiomac.2020.06.039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
35 Krzyżek P, Paluch E, Gościniak G. Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori. Antibiotics (Basel) 2020;9:E658. [PMID: 33007899 DOI: 10.3390/antibiotics9100658] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
36 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
37 Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics (Basel) 2020;9:E589. [PMID: 32916937 DOI: 10.3390/antibiotics9090589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol 2020;15:1185-96. [PMID: 32954842 DOI: 10.2217/fmb-2020-0084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
39 Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020;25:e12714. [PMID: 32533599 DOI: 10.1111/hel.12714] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
40 Cai Y, Wang C, Chen Z, Xu Z, Li H, Li W, Sun Y. Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux. Helicobacter 2020;25:e12715. [PMID: 32548895 DOI: 10.1111/hel.12715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
41 Boyanova L, Markovska R, Medeiros J, Gergova G, Mitov I. Delafloxacin against Helicobacter pylori, a potential option for improving eradication success? Diagnostic Microbiology and Infectious Disease 2020;96:114980. [DOI: 10.1016/j.diagmicrobio.2019.114980] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 BaniHani MN, Khabour OF, Alzoubi KH, Bashir NA, Shakhatreh MAK, Sabi SH, Alrabadi N. The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians. Genes (Basel) 2020;11:E63. [PMID: 31948121 DOI: 10.3390/genes11010063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]